European Network for Translational Research in Atrial Fibrillation (EUTRAF)

At a Glance
  • Status: Active Consortium
  • Year Launched: 2010
  • Initiating Organization: European Commission Seventh Framework Programme (FP7)
  • Initiator Type: Government
  • Disease focus:
    Atrial Fibrillation

Abstract

The European Network for Translational Research in Atrial Fibrillation (EUTRAF) consortium brings together investigators aiming to accelerate knowledge in the pathophysiology and treatment of Atrial Fibrillation. By integrating the mutually complementary strengths and expertise from molecular and cellular electrophysiology to the study of large cohort of patients, EUTRAF aims to develop approaches for increasing knowledge of the arrhythmogenic substrate, with the ultimate goal of developing novel treatments and diagnostic tools.

Mission

The European Network for Translational Research in Atrial Fibrillation (EUTRAF) consortium aims to develop approaches for increasing knowledge of the arrhythmogenic substrate, with the ultimate goal of developing novel treatments and diagnostic tools for atrial fibrillation.

To do this, the goals of the consortium are to: identify cellular and molecular interactions between stromal and parenchumal cells in atrial fibrillation; identify and validate ion channels and transporters for the treatment of persistent atrial fibrillation; identify etiology-specific mechanisms in atrial fibrillation; identify and test in the pre-clinical setting new “upstream” therapeutic targets for sustained atrial fibrillation; translate the genetic contributors to atrial fibrillation into therapeutic targets; develop new diagnostic tools; characterize atrial substrate and conduct proof-of-concept therapeutic clinical studies; develop an IT infrastructure to accelerate knowledge discovery.

Consortium History

November 2010--Project Launch, January 2011--Project Kick off meeting at St. George's University London, October 2011--Month 12 meeting at University of Maastricht, June 2013--Svetlana Reilly Recieves Prize for oral presentation. November 2013--3rd Annual Meeting & project review. February 2014--First issue of EUTRAF newsletter circulated. November 2014--4th annual meeting hosted by Universitaetsklinkikum Essen.

Financing

The "European Network for translational research in atrial fibrillation" (EUTRAF) was granted a total amount of 12 M euros for integrated research through EU FP7 in order to explore disease mechanisms and to develop better diagnostic means and new therapies in patients with atrial fibrillation.

Data Sharing

One of the workstreams aims to create an IT infrastructure that is capable of combining and sharing biomarker data associated with atrial fibrillation.

Homepage

http://www.eutraf.eu

Sponsors & Partners

ST. George’s University of London

Maastricht University (CARIM)

Universite Pierre Marie Curie – Paris 6

Technische Universitat Dresden

Centre Hospitalier Universitaire de Bordeaux

Westfaelische Wilhems-Universitaet Muenster

Otto-von-Guericke University Magdeburg

Universitaet Bern

Medizinische Universitaet Graz

Medical Information Technology Solutions (MITS)

University of Oxford

UK Health and Environment Research Institute

Sanofi-Aventis Deutschland GmbH

Osypka AG

Xention Ltd

Philipps-Universitat Marburg

Ernst-Mortiz-Arndt Universitat

University of Birmingham

Universitaetsklinkikum Essen (UKEssen)


Last Updated: 04/15/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.